ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP)
Promoting Openness, Full Disclosure, and Accountability
FYI
Our criticism of a high risk, speculative drug experiment conducted on
healthy children and adolescents at Yale University's Psychiatric Institute
was validated by a federal investigation: and our criticism is now validated
by the principle investigator, Dr. Thomas McGlashan. Dr. McGlashan, who now
concedes that his screening test proved unreliable. Furthermore. he said:
"I'm more pessimistic about all this now. I don't think the drugs can
prevent full-blown psychosis, only delay it." He added, "I think more than
ever we need to follow a group of prodromal adolescents who get no drug
treatment to see more clearly what happens and refine our understanding of
what the prodrome is."
A profile of Dr. McGlashan, Director of Yale Psychiatric Institute and
professor of psychiatry, was published in The New York Times Science
section, "A Career That Has Mirrored Psychiatry's Twisting Path." The
profile follows a Times news report (May 1) revealing that this
controversial (we maintain, unethical) experiment failed. The authors
reported that "the drugs were more likely to induce weight gain than to
produce a significant, measurable benefit. [And] more than two-thirds of the
participants dropped out, rendering the trial inconclusive."
This unethical experiment was funded by Eli Lilly and the National Institute
of Mental Health. The children (12 years old +) did not qualify for a
diagnosis of any mental illness. Yet, they were exposed for one year to the
severe risks and health hazards linked to Lilly's antipsychotic drug,
Zyprexa (olanzapine) merely because the Yale investigators presumed the
adolescents were "at risk" of schizophrenia-without scientific evidence to
back up that presumption. See: http://www.ahrp.org/cms/content/view/157/80/
Link http://www.ahrp.org/cms/
Promoting Openness, Full Disclosure, and Accountability
FYI
Our criticism of a high risk, speculative drug experiment conducted on
healthy children and adolescents at Yale University's Psychiatric Institute
was validated by a federal investigation: and our criticism is now validated
by the principle investigator, Dr. Thomas McGlashan. Dr. McGlashan, who now
concedes that his screening test proved unreliable. Furthermore. he said:
"I'm more pessimistic about all this now. I don't think the drugs can
prevent full-blown psychosis, only delay it." He added, "I think more than
ever we need to follow a group of prodromal adolescents who get no drug
treatment to see more clearly what happens and refine our understanding of
what the prodrome is."
A profile of Dr. McGlashan, Director of Yale Psychiatric Institute and
professor of psychiatry, was published in The New York Times Science
section, "A Career That Has Mirrored Psychiatry's Twisting Path." The
profile follows a Times news report (May 1) revealing that this
controversial (we maintain, unethical) experiment failed. The authors
reported that "the drugs were more likely to induce weight gain than to
produce a significant, measurable benefit. [And] more than two-thirds of the
participants dropped out, rendering the trial inconclusive."
This unethical experiment was funded by Eli Lilly and the National Institute
of Mental Health. The children (12 years old +) did not qualify for a
diagnosis of any mental illness. Yet, they were exposed for one year to the
severe risks and health hazards linked to Lilly's antipsychotic drug,
Zyprexa (olanzapine) merely because the Yale investigators presumed the
adolescents were "at risk" of schizophrenia-without scientific evidence to
back up that presumption. See: http://www.ahrp.org/cms/content/view/157/80/
Link http://www.ahrp.org/cms/
No comments:
Post a Comment